Trial Profile
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adolescent ADHD Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Rhodes Pharmaceuticals
- 01 Nov 2021 Results published in the Journal of Child and Adolescent Psychopharmacology
- 16 Jan 2020 Results published in Adlon Therapeutics L.P.and Purdue Pharma media release Media Release
- 16 Jan 2020 According to a Adlon Therapeutics L.P.and Purdue Pharma media release, data from this trial will be presented at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting in Washington D.C.